KrystoLens from Brain Navi Receives TFDA Certification, Set to Enter Taiwan Market

Brain Navi Biotechnology Achieves Key Regulatory Milestone Following Recognition at the 22nd National Innovation Award

ZHUBEI, June 3, 2026 /PRNewswire/ — Brain Navi Biotechnology announced that its KrystoLens, the single-use neuro-endoscope, has officially received certification from the Taiwan Food and Drug Administration (TFDA), marking an important milestone in the company’s development in medical imaging and endoscopic applications.

Following its recognition at the 22nd National Innovation Award earlier this year, KrystoLens has once again gained attention for its product innovation and clinical potential. The TFDA certification confirms that the product complies with Taiwan’s medical device regulatory requirements and paves the way for its formal introduction into the local healthcare market.

Sign up for Blog Updates